文献速递泌尿男性生殖肿瘤

舒尼替尼2周用药1周停药方案治疗转移性肾细胞癌的II期研究

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
PubMed 文献 · J Clin Oncol · 2018-04-11

该II期研究评估舒尼替尼2周用药1周停药(2/1)方案在初治转移性肾细胞癌患者中的毒性和疗效。主要终点为≥3级疲劳、腹泻或手足综合征发生率低于15%,但实际25%患者发生≥3级毒性,未达到主要终点;然而无4级毒性,停药率低(10%),客观缓解率57%,中位无进展生存13.7个月。

要点

  • 2/1方案未达到主要终点:25%患者发生≥3级疲劳、手足综合征或腹泻。
  • 无4级毒性,仅10%因毒性停药,37%需减量。
  • 客观缓解率57%,中位无进展生存13.7个月,中位总生存未达到。

核心结论

  • 2/1方案未降低≥3级毒性至预设阈值以下,但无4级毒性、停药率低且疗效高。

研究设计与样本

  • 主要终点为≥3级疲劳、腹泻或手足综合征发生率低于15%。

主要发现

  • 中位随访17个月,25%患者发生≥3级疲劳、手足综合征或腹泻。
  • 37%患者需减量,10%因毒性停药。
  • 客观缓解率57%,中位无进展生存13.7个月,中位总生存未达到。
  • 12周时FACT-G评分较基线下降0%至10%,治疗时间较长者下降较少。

关键数值与推荐

  • 主要终点阈值:≥3级疲劳、腹泻或手足综合征发生率<15%。
  • 实际≥3级毒性发生率25%,未达到主要终点。

临床怎么用

  • 2/1方案可作为转移性肾细胞癌的替代选择,尤其关注无4级毒性和低停药率。
  • 需密切监测毒性并适时调整剂量,37%患者需减量。

局限性

  • 主要终点未达到,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with sunitinib includes the development of significant adverse effects, including diarrhea, hand-foot syndrome (HFS), and fatigue. This trial assessed the effect of an alternate 2 weeks on, 1 week off (2/1) schedule of sunitinib on toxicity and efficacy in previously untreated patients with metastatic renal cell carcinoma. Methods Patients started with oral administration of 50 mg sunitinib on a 2/1 schedule and underwent schedule and dose alterations if toxicity developed. The primary end point was < 15% grade ≥ 3 fatigue, diarrhea, or HFS. With 60 patients, the upper bound of the CI would fall below the published 4/2 schedule grade ≥ 3 toxicity rate of 25% to 30%. Results Fifty-nine patients were treated between August 2014 and March 2016. Seventy-seven percent were intermediate or poor risk per Memorial Sloan Kettering Cancer Center criteria. With a median follow-up of 17 months, 25% of patients experienced grade 3 fatigue, HFS, or diarrhea; 37% required a dose reduction, and 10% discontinued because of toxicity. The overall response rate was 57%, median progression-free survival was 13.7 months, and median overall survival was not reached. At 12 weeks, Functional Assessment of Cancer Therapy-General scores dropped between 0% and 10% from baseline, with less reduction in patients who continued treatment longer. Conclusion The primary end point of decreased grade 3 toxicity was not met; however, treatment with a 2/1 sunitinib schedule is associated with a lack of grade 4 toxicity, a low patient discontinuation rate, and high efficacy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jonasch E, Slack RS, Geynisman DM, et al. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2018. PMID: 29641297. doi:10.1200/JCO.2017.77.1485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。